Proteocyte Receives Support from NRC-IRAP for Straticyte™ Intellectual Property Development
Proteocyte Diagnostics Inc. today announced the completion of a project enhancing the current version of Straticyte™ and opening up new potential applications. This significant advancement has led to additional Intellectual Property and value creation for the Company.
Vive Crop Protection Receives EPA Registration for Bifender At-Plant Insecticide
The United States Environmental Protection Agency has approved Vive Crop Protection's Bifender™ insecticide using Vive's proprietary Allosperse® delivery technology. The product contains bifenthrin, an excellent broad-spectrum insecticide, and is targeted for early-season in-furrow or soil applications.
CAAP Company: Induce Biologics Signs Exclusive License & Distribution Agreement with Antibe Therapeutics
January 12, 2016, Toronto — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF), a commercial-stage healthcare company focused on pain, inflammation and regenerative medicine, is pleased to announce the signing of an exclusive Licensing and Distribution Agreement with Induce Biologics Inc. (“Induce”) for the Canadian rights for Induce’s URIST(TM) biological product for dental and craniofacial applications.
For the full press release click here
Sernova Corp to Present at the Biotech Showcase(TM) 2016 in San Francisco on January 13, 2016
Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, today announced that Dr. Philip Toleikis, Sernova’s President and CEO, will be providing a corporate update at the 8th annual Biotech Showcase Conference in San Francisco, CA, at 4:00 p.m. PST on January 13, 2016 in San Francisco, California.
In a full roster of business development meetings, Dr. Toleikis will also be updating key pharma and institutional audiences on the company's progress and future plans.
Gail Garland, OBIO CEO talks with BNN about Canada's health science industry
Gail Garland, OBIO CEO talks with BNN about the economic and health benefits that accrue to Canada by building a globally competitive Canadian health science industry. Click here for the full interview.
Proteocyte Receives Support from NRC-IRAP for Straticyte™
Proteocyte Diagnostics Inc. today announced the completion of a project enhancing the current version of Straticyte™ and opening up new potential applications.
SERNOVA AWARDED EUROPE’S PRESTIGIOUS HORIZON 2020 GRANT
Distinguished European consortium awarded approximately $8.5 Million CAD by the European Commission via its Horizon 2020 Program to partner advanced cell based Factor VIII therapy in collaboration with Sernova and its Cell Pouch(TM) device technologies.
Canada shows a “disturbing” decline in innovation and R&D
Read the Canadian Business article on the recently released STIC report.
OBIO® MPP Health Science Caucus Launches Three Party Effort to Advance Industry
Toronto, Ontario, December 3, 2015 – OBIO announced today that MPPs from the three major parties have come together to work on policy initiatives to strengthen Ontario’s Health Science industry.
Dose of the Valley - Call for Applications
For the second year, the Consulate General of Canada in San Francisco and the Consulate of Canada in San Diego are pleased to host the Dose of the Valley program for the life sciences sector.
Launch of the second Canada-Chicago Mentoring Program (C2MP)
The Consulate General of Canada in Chicago successfully partnered in 2015 (testimonials included in our enclosed marketing document for the 2016 program) with the Chicago Innovation Mentors (CIM) to provide a comprehensive mentoring program for three Canadian life science and healthcare entrepreneurs.
It is our pleasure to announce that the program has been renewed for 2016. The Consulate will again be able to funnel three Canadian start-ups through CIM’s mentoring program.
Canada needs a strategy to reach its biotech potential
Canada has a well-known research sector and relatively strong infrastructure to nurture startups, but once biotech companies start to grow, they often stall and struggle for resources.
Ontario Bioscience Innovation Organization Announces Election of Shelley Boyd, Jeremy Bridge-Cook, Michael Cloutier and Cathy Szabo to its Board of Directors
Toronto, Ontario, November 4, 2015 – Ontario Bioscience Innovation Organization (“OBIO®”), a non-profit organization that is Ontario’s leading advocate for the life science sector, announces the election of four new members to its Board of Directors: Shelley Boyd, Jeremy Bridge-Cook, Michael Cloutier and Cathy Szabo.
Ontario Bioscience Innovation Organization Announces a Call for Applications for the 2016 Capital Access Advisory Program
Toronto, Ontario, November 3, 2015 – Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit organization that is Ontario’s leading advocate for the life sciences sector, is pleased to announce a call for applications for the 2016 OBIO Capital Access Advisory Program (CAAP®).
Ontario Bioscience Innovation Organization Congratulates Ontario on the Appointment of Chief Health Innovation Strategist
Today, Ontario Bioscience Innovation Organization (OBIO®) released a statement congratulating the Government of Ontario on the appointment of William Charnetski as Ontario’s first Chief Health Innovation Strategist.
“OBIO congratulates Mr. Charnetski on his appointment to this pivotal role,” said Gail Garland, Chief Executive Officer of OBIO. “We look forward to supporting his efforts to catalyze adoption of innovative health technologies which strengthen the province’s capacity to deliver cost-effective, outcome-focused care for patients.”
OBIO Congratulates and Welcomes Johnson & Johnson Innovation, JLABS to the Ontario Bioscience Ecosystem
Toronto, Ontario, September 21, 2015 – The Ontario Bioscience Innovation Organization (OBIO®) is pleased to recognise Johnson & Johnson Innovation’s major contribution to Ontario’s human health bioscience ecosystem through the choice of Toronto as the first ex-US Johnson & Johnson Innovation, JLABS site. The JLABS incubator model is the highly successful creation of Johnson & Johnson Innovation and has been brought to Canada with the help of Janssen Inc. Known as JLABS @ Toronto, the site will join its fellow JLABS sites in San Diego, San Francisco, Boston and Houston.
Pre-Capital Access Advisory Program (Pre-CAAP)
OBIO Launches Pre-Capital Access Advisory Program (Pre-CAAP) – Builds on Successful Capital Access Advisory Program (CAAP™) Improving financing success of Ontario bioscience companies Toronto, Ontario, August 10, 2015 – Ontario Bioscience Innovation Organization (OBIO®) today announced the launch of the inaugural round of Pre-CAAP, a program in support of Ontario bioscience companies that aim to raise...
OBIO CAAP Program Receives FedDev Ontario Funding
Toronto, Ontario, May 22, 2015 – Ontario Bioscience Innovation Organization (OBIO®) today announced they have received an investment of up to $3.894 million from the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) for OBIO®’s Capital Access Advisory Program (CAAP™).
“It is tremendous to see this practical support for commercializing health sciences and for building our human health bioscience industry,” said Gail Garland, President and CEO, OBIO®. “We are deeply grateful for this opportunity to expand our programming and help even more growing companies.”
2015 Healthcare Conferences
OBIO/OBEST Five Year Strategic Review: January 2015
Since its founding, the Ontario Bioscience Innovation Organization (OBIO®) has been engaged in creating the future of Ontario’s biomedical sector through industry-led strategy, policy development, advocacy and high impact programming.